Compare Ginkgo Bioworks Holdings Inc (DNA) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Otis Worldwide Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.44 (market cap $505.73M), while Otis Worldwide Corp trades at $73.5 (market cap $27.80B). The key difference: Otis Worldwide Corp is far larger — about 55× Ginkgo Bioworks Holdings Inc's market cap, and Otis Worldwide Corp pays a 2.41% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | OTIS | |
|---|---|---|
Market Cap | $505.73M | $27.80B |
Sector | Health | Industrials |
52-Week High | $16.14 | $93.62 |
52-Week Low | $5.48 | $69.34 |
Enterprise Value | $607.68M | $35.84B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Otis Worldwide (OTIS) trades at $72.87, down 1.51% over 24 hours, with a neutral technical signal and bearish moving averages. Recent Q2 2026 earnings beat estimates but saw margin pressures and full-year guidance cuts. The company maintains strong service segment growth, with 9% organic sales increase, while facing headwinds in new equipment demand and labor costs. Valuation metrics show a P/E of 18.78 and P/S of 1.91, below historical averages after a 19% year-to-date decline.
Outlook is mixed: analyst consensus targets $92.50 with 47% buy ratings, but near-term risks include persistent margin compression and weak equipment sales. Long-term potential hinges on service margin expansion and modernization backlog execution, though investor sentiment remains cautious amid earnings misses and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
